Press Releases

SYDNEY--(BUSINESS WIRE)-- James Hardie today announced results for the second quarter of fiscal year 2019 and the half year ended 30 September 2018: Group Adjusted net operating profit of US$80.9 million for the quarter and US$160.8 million for the half year, an increase of 7% and 17%, respectively, compared to the prior corresponding periods (“pcp”);

SAN DIEGO--(BUSINESS WIRE)-- Innovative Industrial Properties, Inc. (NYSE: IIPR) (the "Company"), the leading provider of creative capital solutions to the medical-use cannabis industry, announced today results for the quarter ended September 30, 2018, the seventh full quarter since the Company commenced real estate operations and completed its initial public offering in December 2016. Thir

CULVER CITY, Calif.--(BUSINESS WIRE)-- The recent successes of immunotherapy, such as checkpoint inhibition, have spawned a wave of enthusiasm for immuno-oncology. Unfortunately, only a subset of cancer patients respond to checkpoint inhibitor monotherapy, and many of these checkpoint-responsive patients will eventually relapse. In addition, cellular therapy in the form of CAR-T cells has shown little evidence

SINGAPORE--(BUSINESS WIRE)-- The National Additive Manufacturing Innovation Cluster (NAMIC) today signed a memorandum of understanding with

WILLIAMSVILLE, N.Y.--(BUSINESS WIRE)-- 22nd Century Group, Inc. (NYSE American:XXII), a plant biotechnology company that is focused on tobacco harm reduction, V

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Add after last paragraph of release: two financial tables. The updated release reads: RA PHARMACEUTICALS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE Dosing completed in Phase 2 trial of zilucoplan in generalized myasthenia gravis

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced financial results for the third quarter ended September 30, 2018 and highlighted recent progress in advancing its pipeline programs, including zilucoplan for the treatment of generalized myasthenia gravis (gMG), paroxysmal nocturnal hemoglobinuria (PNH), and complement-mediated renal disorders. “We are pl

DALLAS--(BUSINESS WIRE)-- Flowserve Corporation (NYSE: FLS), a leading provider of flow control products and services for the global infrastructure markets, today announced its financial results for the third quarter ended September 30, 2018. Third Quarter 2018 Highlights (all comparisons to the 2017 third quarter, unless otherwise noted)

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Kebotix (www.kebotix.com), a technology company ushering in the future of new materials discovery, today came out of stealth mode with a $5 mi

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Synlogic, Inc. (Nasdaq: SYBX), announced today that the Company will release its third quarter 2018 financial result

AUGSBURG, Germany--(BUSINESS WIRE)-- voxeljet AG (NYSE: VJET) has launched its new VX1000-S IOB printing system for serial production of sand cores for aluminium casting. So far, the company focused on organic printing processes in its sand printing line of business. The new VX1000-S IOB inorganic system significantly improves throughput and ensures high environmental compatibility during the whole process.

ORANGE, Texas--(BUSINESS WIRE)-- INVISTA’s site in Orange, Texas, set a 12-month production record for adiponitrile (ADN), a key ingredient for nylon 6,6 plastics and fibers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181107005904/en/

PASADENA, Calif.--(BUSINESS WIRE)-- Tetra Tech, Inc. (NASDAQ: TTEK) today announced results for the fourth quarter and fiscal year ended September 30, 2018. Fourth Quarter Results Revenue in the fourth quarter totaled $739 million. For ongoing1 operations, revenue totaled $747 million, and revenue, net of subcontractor costs2 (net revenue), was $564 million, up

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Stifel 2018 Healthcare Conference on Wednesday, November 14, 2018 at 09:30 A.M. ET in New York, NY. A live webcast

ORLANDO, Fla.--(BUSINESS WIRE)-- The LGL Group, Inc. (NYSE American: LGL) (the “Company” or “LGL”), announced its financial results for the three and nine months ended September 30, 2018. Summary of Q3 2018 Financial Results: Revenues of $6.3 million, up 20.4% compared to Q3 2017 of $5.3 million